Your browser doesn't support javascript.
loading
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Rini, Brian I; Powles, Thomas; Atkins, Michael B; Escudier, Bernard; McDermott, David F; Suarez, Cristina; Bracarda, Sergio; Stadler, Walter M; Donskov, Frede; Lee, Jae Lyun; Hawkins, Robert; Ravaud, Alain; Alekseev, Boris; Staehler, Michael; Uemura, Motohide; De Giorgi, Ugo; Mellado, Begoña; Porta, Camillo; Melichar, Bohuslav; Gurney, Howard; Bedke, Jens; Choueiri, Toni K; Parnis, Francis; Khaznadar, Tarik; Thobhani, Alpa; Li, Shi; Piault-Louis, Elisabeth; Frantz, Gretchen; Huseni, Mahrukh; Schiff, Christina; Green, Marjorie C; Motzer, Robert J.
Afiliação
  • Rini BI; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: rinib2@ccf.org.
  • Powles T; Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, UK.
  • Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Escudier B; Gustave Roussy, Villejuif, France.
  • McDermott DF; Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Suarez C; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Bracarda S; Azienda Ospedaliera S Maria, Terni, Italy.
  • Stadler WM; The University of Chicago Medicine, Chicago, IL, USA.
  • Donskov F; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Lee JL; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Hawkins R; The Christie NHS Foundation Trust, Manchester, UK.
  • Ravaud A; CHU Hôpitaux de Bordeaux-Hôpital Saint-André, Bordeaux, France.
  • Alekseev B; P Herzen Oncology Research Institute, Moscow, Russia.
  • Staehler M; Klinikum der Universität München, Campus Großhadern, München, Germany.
  • Uemura M; Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • De Giorgi U; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy.
  • Mellado B; Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Porta C; IRCCS San Matteo University Hospital Foundation, Pavia, Italy.
  • Melichar B; Lékarská Fakulta Univerzita Palackého a Fakultní Nemocnice Olomouc, Olomouc, Czech Republic.
  • Gurney H; Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia.
  • Bedke J; Department of Urology, University of Tübingen, Tübingen, Germany.
  • Choueiri TK; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Parnis F; Ashford Cancer Centre Research, Kurralta Park, SA, Australia.
  • Khaznadar T; F Hoffmann-La Roche, Basel, Switzerland.
  • Thobhani A; Roche Products Ltd, Welwyn Garden City, UK.
  • Li S; Genentech, Inc, South San Francisco, CA, USA.
  • Piault-Louis E; Genentech, Inc, South San Francisco, CA, USA.
  • Frantz G; Genentech, Inc, South San Francisco, CA, USA.
  • Huseni M; Genentech, Inc, South San Francisco, CA, USA.
  • Schiff C; Genentech, Inc, South San Francisco, CA, USA.
  • Green MC; Genentech, Inc, South San Francisco, CA, USA.
  • Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lancet ; 393(10189): 2404-2415, 2019 06 15.
Article em En | MEDLINE | ID: mdl-31079938
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Bevacizumab / Sunitinibe / Neoplasias Renais / Anticorpos Monoclonais / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2019 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Bevacizumab / Sunitinibe / Neoplasias Renais / Anticorpos Monoclonais / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2019 Tipo de documento: Article País de publicação: Reino Unido